Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: MDXG

MiMedx Group, Inc.

Healthcare | Biotechnology

No licensed closing price on file for MDXG. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$0.04

MiMedx Group, Inc. (NASDAQ: MDXG) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 02:26 UTC.

What MiMedx Group, Inc. does

MIMEDX develops and distributes products to help clinicians treat chronic and hard-to-heal wounds, burns, and surgical conditions. The company historically focused on placental tissue-based products manufactured through its proprietary PURION process, sourcing donated birth tissue from hospitals and clinician networks and processing it in facilities in Marietta, Georgia. Beginning in 2024, MIMEDX broadened its portfolio to include animal-derived products and entered into distribution agreements for additional wound care solutions manufactured by third parties.

Summarized from MiMedx Group, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
EPS (TTM)$0.04
Return on equity18.94%
Debt/equity0.07

Revenue, margins & earnings

FY2021: net loss $10M on revenue $242M$242MFY2021FY2022: net loss $30M on revenue $268M$268MFY2022FY2023 Revenue: $321M — margin split not shown (non-operating gains)$321MFY2023FY2024 Net income: $42MFY2024 Taxes & interest: $16MFY2024 Operating expenses: $230MFY2024 Cost of revenue: $60M$349MFY2024FY2025 Net income: $49MFY2025 Taxes & interest: $15MFY2025 Operating expenses: $282MFY2025 Cost of revenue: $73M$419MFY2025
  • Net income
  • Taxes & interest
  • Operating expenses
  • Cost of revenue
  • Net loss year
Annual revenue; bands show net, operating, gross margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity
Source: SEC EDGAR · Filed 2026-07-07
Most recent filed transactions — July 2026:
  • 2026-07-07Chief Financial OfficerTax withholding-12,749$50.4K
  • 2026-06-25Chief Commercial OfficerTax withholding-19,820$75.9K
  • 2026-06-12DirectorAward50,913$185.3K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does MiMedx Group, Inc. do?

MIMEDX develops and distributes products to help clinicians treat chronic and hard-to-heal wounds, burns, and surgical conditions.

When did MDXG last file with the SEC?

MiMedx Group, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-16. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 02:26 UTC. This page is also available as JSON at /api/data?ticker=MDXG and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for MDXG and 5,000+ tickers.

Create a free account — keep MDXG
For your agent
GET /api/data?ticker=MDXG

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt